Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Stoke Therapeutics, Inc. STOK
$11.45
-$0.05 (-0.48%)
На 18:01, 12 мая 2023
+262.45%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
515679795.00000000
-
week52high
22.87
-
week52low
6.88
-
Revenue
12405000
-
P/E TTM
-5
-
Beta
0.40707900
-
EPS
-2.78000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 12:30
Описание компании
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Needham | Buy | Buy | 08 авг 2022 г. |
| Cantor Fitzgerald | Overweight | Overweight | 26 мая 2022 г. |
| B of A Securities | Buy | Buy | 16 мар 2022 г. |
| Jefferies | Buy | 31 янв 2022 г. | |
| B of A Securities | Buy | 03 дек 2021 г. | |
| Needham | Buy | Buy | 14 ноя 2022 г. |
| Credit Suisse | Outperform | Outperform | 15 ноя 2022 г. |
| Credit Suisse | Outperform | Outperform | 11 янв 2023 г. |
| HC Wainwright & Co. | Buy | Buy | 05 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Ticho Barry | D | 124723 | 267 | 02 февр 2023 г. |
| Ticho Barry | D | 124990 | 5705 | 01 февр 2023 г. |
| Ticho Barry | D | 130695 | 200 | 31 янв 2023 г. |
| Tulipano Stephen J | A | 62000 | 62000 | 07 дек 2022 г. |
| Nash Huw M. | A | 62000 | 62000 | 07 дек 2022 г. |
| Ticho Barry | A | 62000 | 62000 | 07 дек 2022 г. |
| Kaye Edward M. MD | A | 167050 | 167050 | 07 дек 2022 г. |
| Smith Julie | A | 21000 | 21000 | 07 июн 2022 г. |
| TZIANABOS ARTHUR | A | 21000 | 21000 | 07 июн 2022 г. |
| Krainer Adrian R. | A | 21000 | 21000 | 07 июн 2022 г. |
Новостная лента
How Much Upside is Left in Stoke Therapeutics, Inc. (STOK)? Wall Street Analysts Think 102.91%
Zacks Investment Research
09 мая 2023 г. в 11:27
The consensus price target hints at a 102.9% upside potential for Stoke Therapeutics, Inc. (STOK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
04 мая 2023 г. в 10:41
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $0.66 per share a year ago.
Stoke Therapeutics to Present at the BofA Securities Health Care Conference
Business Wire
03 мая 2023 г. в 08:00
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the BofA Securities Health Care Conference on Thursday, May 11, 2023, at 11:00 a.m. ET. (8:00 a.m. PT) A live webcast of the presentation, which will be conducted in fireside chat format, will be available on the Investors &.
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
06 мар 2023 г. в 09:47
Stoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of 9.72% and 11.42%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Stoke Therapeutics to Participate at Upcoming March Investor Conferences
Business Wire
27 февр 2023 г. в 16:30
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will be participating at the following upcoming investor conferences: Cowen 43rd Annual Health Care Conference Date: Monday, March 6, 2023 Time: 12:50 p.m.